linjc16/ctgov huggingface dataset:
VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

Study Overview
=================
Brief Summary
-----------------
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).

Official Title
-----------------
VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis

Conditions
-----------------
Chronic Bronchitis, Disease Exacerbation

Intervention / Treatment
-----------------
* Drug: Moxifloxacin (Avelox, BAY12-8039)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients at least 18 years of age with a diagnosis of AECB treated with Moxifloxacin injection with/without sequential tablet treatment Exclusion Criteria: Exclusion criteria must be read in conjunction with the local product information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Moxifloxacin (Avelox, BAY12-8039)<br>* Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical cure rate:clinical cure was defined as disappearance of acute signs and symptoms |  | up to 21 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to cure: time when symptoms are disappeared after Moxifloxacin treatment |  | up to 21 days | 
| Improvement time: time when patients feel improvemen |  | up to 21 days | 
| Time of patients recover from fever |  | up to 21 days | 
| Clinical efficacy rate of Moxifloxacin |  | up to 21 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Exacerbations of Chronic Bronchitis, Avelox, Bronchitis
Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid

Study Overview
=================
Brief Summary
-----------------
Papillary thyroid microcarcinoma (PTMC), defined as a tumor with larger diameter ≤ 1 cm, is considered a tumor with an indolent course and an excellent prognosis. Nevertheless, the incidence of lymph node metastasis in PTMC is not negligible, reaching up to 65% in some series. The aim of this study was to assess the incidence of lymph node metastasis in patients with PTMC and to evaluate predictive factors for lymph node metastasis.

Official Title
-----------------
Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid

Conditions
-----------------
Thyroid Cancer, Lymph Node Metastases

Intervention / Treatment
-----------------
* Procedure: Thyroidecomt and lymphectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with papillary microcarcinoma of the thyroid Exclusion Criteria: Patients with thyroid nodules > 1 cm; incomplete data
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PTMC<br>Patients with papillary microcarcinoma of the thyroid | Procedure: Thyroidecomt and lymphectomy<br>* Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of lymph node metastasis | To define the incidence of lymph node metastasis in patients with papillary microcarcinoma | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predicrive factors of lymph node metastasis | To assesss predictive factors of lymph node metastasis | 1 year |
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.

Official Title
-----------------
NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-positive Locally Advanced Breast Cancer Patients

Conditions
-----------------
Breast Cancer Female

Intervention / Treatment
-----------------
* Drug: Pyrotinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, Aged ≥18 and ≤70 years Histologically confirmed invasive HER2 positive breast cancer, early disease(Stage ⅡA-Ⅲ) Subjects with at least one evaluable lesion ECOG 0-1 Adequate organ function Exclusion Criteria: Metastatic disease (Stage IV) Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption Treated or treating with T-DM1, lapatinib and neratinib before study entry History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test. Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: neoadjuvant pyrotinib<br>pyrotinib 400mg qd trastuzumab 4mg/kg loading dose, then 2mg/kg qw palitaxel 80mg/m^2, d1, 8, 15, 22 cisplatin 25mg/m^2, d1, 8, 15 every 28 days | Drug: Pyrotinib<br>* dual HER2 blockade in the neoadjuvant setting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pCR | pathological complete response | 1-2 weeks after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neoadjuvant, pyrotinib, trastuzumab, paclitaxel, cisplatin